VIR201 South African Trial First patient Vaccinated - 11 Dec 2008
AGM 2008 Chairman and CEO Addresses - 26 Nov 2008
AGM CEO Slide Presentation - 26 Nov 08
AGM Results - 26 Nov 2008
Convertible Notes - Quarterly Report 30 September 08
Notice of AGM 2008 Mailing - 27 October 2008
Transgene TG4010 Update - 17 September 2008
Transgene Update - 12 September 2008
Appendix 3Y - 1 September 2008
Appendix 4E - 30 June 2008
Appendix 3Y - 25 August 2008
Appendix 3Y - 20 August 2008
Appendix 3B & Cover letter - 18 August 2008
Shareholding Update ANZ - Opes Prime - 12 August 2008
SA Trial approval- 8 August 2008
Convertible Notes - Quarterly Report to Trust and ASIC - 31 July 08
Appendix 3Y - 8 July 2008
Convertible Notes and Quarterly Report to Trust & ASIC
Shareholding Update and Convertible Note Placement
Appendix 3Y - Notice of Change of Directors' Interest
Appendix 3X - Amendment to previous announcement released on 22 January 2008.
Appendix 3B - Registration of Convertible Notes
Appendix 4D - Financial Report for the half year ended 31 December 2007.
90% of Donor Syndicate Complete
Virax Holdings Limited (ASX: VHL) today announced it had raised $1.88 million through its most recent rights issue of convertible notes.
VIR201 PHASE IIa TRIAL RESULTS NOW PUBLISHED IN PEER REVIEWED SCIENTIFIC JOURNAL – HUMAN VACCINES
Chairman's Letter describing Fund Raising and the Corporate Strategy
Technology License with Transgene Interim Results
Appendix 3X - Initial Notice of Directors' Interest
Appendix 3Z - Final Notice of Director' Interest
Convertible Note Issue - Amended Closing Date and Despatch Date
Board Changes Completed and Extension of Rights Issue Closing Date
Minimum Subscription Achieved, Board Changes and Desptach of Prospectus